Your new post is loading...
Your new post is loading...
|
Scooped by
Gilbert C FAURE
December 16, 2013 2:45 AM
|
Resources for DIU Immunologie et Biothérapies
DIU Immunologie et Biotherapies is a french diploma associating french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular.
|
Scooped by
Gilbert C FAURE
May 27, 11:42 AM
|
Le 24 mai, des chercheurs chinois ont annoncé avoir transplanté avec succès un foie de porc génétiquement modifié sur un patient humain vivant atteint d’un cancer du foie.
|
Scooped by
Gilbert C FAURE
May 5, 2:48 AM
|
A l'Institut de recherche sur les dispositifs médicaux de Suzhou de l'Université du Sud-Est, situé à Suzhou, dans la province chinoise du Jiangsu (est), on a...
|
Scooped by
Gilbert C FAURE
April 28, 12:56 PM
|
SignificanceRespiratory virus infections in humans are a significant global health concern, causing a wide range of diseases with substantial morbidity and mortality worldwide. This underscores the...
|
Scooped by
Gilbert C FAURE
April 24, 5:04 AM
|
Aspirin, taken by around 29 million Americans daily, has increasingly been linked to inhibiting the growth of certain cancers – but we didn't quite know how. Now, scientists have uncovered how it helps the immune system see and kill cancer cells.
|
Scooped by
Gilbert C FAURE
April 9, 9:22 AM
|
|
Scooped by
Gilbert C FAURE
April 4, 1:43 PM
|
Biotechnology firm LyGenesis has injected donor cells into a person with liver failure for the first time.
|
Scooped by
Gilbert C FAURE
March 29, 6:15 AM
|
Protection results from GSK Shingrix vaccines against #Shingles are impressive. Guess which adjuvant was used?
👉A #TLR4 agonist of course 🦠
The results…
|
Scooped by
Gilbert C FAURE
March 8, 6:13 AM
|
🔸 Actualisation de la stratégie vaccinale contre le zona :
Le zona, causé par la réactivation du virus varicelle-zona, est une maladie virale touchant…
|
Scooped by
Gilbert C FAURE
March 6, 5:21 AM
|
"The modulation of cytokines and cytokine receptors is highly promising for enhancing NK cell survival and persistence, thus paving the way for durable…
|
Scooped by
Gilbert C FAURE
March 5, 3:54 AM
|
|
Scooped by
Gilbert C FAURE
March 3, 4:07 AM
|
Bravo à nos collègues de Barcelone qui ont démontré le bénéfice medico-économique du remboursement des anti-CGRP en Espagne, notamment grâce à la réduction de…
|
Scooped by
Gilbert C FAURE
February 23, 11:27 AM
|
OverviewOn 22 February 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Tizveni, intended for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) either in monotherapy or in combination with chemotherapy. The applicant for this medicinal product is Beigene Ireland Limited.Tizveni will be available as a 100 mg concentrate for solution for infusion. The active substance of Tizveni is tislelizumab, an antineoplastic agent (ATC code: L01FF09). Tislelizumab is a humanised IgG4 variant monoclonal antibody that potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands.The benefit of Tizveni is an improvement in overall survival and progression free survival in patients with locally advanced or metastatic NSCLC, as shown in three open-label, randomised phase 3 studies comparing Tizveni (either in monotherapy or in combination) with chemotherapy. The most common side effects are anaemia, fatigue and increased AST.The full indication is:Tizveni in combination with pemetrexed and platinum‑containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous non-small cell lung cancer whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have:locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, ormetastatic NSCLC.Tizveni in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of adult patients with squamous non-small cell lung cancer who have:locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, ormetastatic NSCLC.Tizveni as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab.Tizveni should be prescribed by physicians experienced in the treatment of cancer.Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.CHMP summary of positive opinion for TizveniAdoptedFirst published: 23/02/2024Reference Number: EMA/CHMP/59203/2024 English (EN) (114.24 KB - PDF)ViewProduct detailsName of medicine Tizveni Active substance Tislelizumab International non-proprietary name (INN) or common name tislelizumab Therapeutic area (MeSH) Carcinoma, Non-Small-Cell Lung Anatomical therapeutic chemical (ATC) code L01FF09 EMA product number EMEA/H/C/005542 Marketing authorisation applicant BeiGene Ireland Ltd Opinion adopted 22/02/2024 Opinion status Positive This page was last updated on 23/02/2024Share this page
|
|
Scooped by
Gilbert C FAURE
June 4, 3:48 AM
|
Notre nouvelle revue sur le monitoring des biothérapies
|
Scooped by
Gilbert C FAURE
May 12, 10:15 AM
|
There are other ways to therapeutically stimulate intratumoral innate immunity - with encouraging clinical results -, including in situ vaccination against the…
|
Scooped by
Gilbert C FAURE
May 2, 5:25 AM
|
|
Scooped by
Gilbert C FAURE
April 25, 10:11 AM
|
Targeting claudin-1 offers a promising approach for treating solid tumours by selectively killing cancer cells and breaking down barriers to immunotherapy.
|
Scooped by
Gilbert C FAURE
April 9, 11:28 AM
|
Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.
|
Scooped by
Gilbert C FAURE
April 5, 3:02 AM
|
✨ Discovering New Horizons on #XENOTRANSPLANTATION ✨
We’re on an exhilarating journey to unravel the mysteries of xeno immune response. Our passion for… | 17 comments on LinkedIn
|
Scooped by
Gilbert C FAURE
March 30, 5:13 AM
|
The study unveils that potent combination therapies remodel TAMs to antitumor proinflammatory M1-like macrophages crucial for their therapeutic efficacy. I
|
Scooped by
Gilbert C FAURE
March 22, 8:08 AM
|
The future of vaccine development in light of accelerated technological advances through the COVID-19 pandemic.
|
Scooped by
Gilbert C FAURE
March 7, 11:30 AM
|
A description of H. Golding's research program and related publications.
|
Scooped by
Gilbert C FAURE
March 5, 11:05 AM
|
Successful approaches for eradication or cure of HIV-1 infection are likely to include immunological mechanisms, but remarkably little is known about how human immune responses can recognize and interact with the few HIV-1-infected cells that harbour genome-intact viral DNA, persist long term despite antiretroviral therapy and represent the main barrier to a cure. For a long time regarded as being completely shielded from host immune responses due to viral latency, these cells do, on closer examination with single-cell analytic techniques, display discrete footprints of immune selection, implying that human immune responses may be able to effectively engage and target at least some of these cells. The failure to eliminate rebound-competent virally infected cells in the majority of persons likely reflects the evolution of a highly selected pool of reservoir cells that are effectively camouflaged from immune recognition or rely on sophisticated approaches for resisting immune-mediated killing. Understanding the fine-tuned interplay between host immune responses and viral reservoir cells will help to design improved interventions that exploit the immunological vulnerabilities of HIV-1 reservoir cells. Finding a cure for HIV-1 infection, once considered elusive, now represents a major priority for the global microbiology research community. In this article, Armani-Tourret, Lichterfeld and colleagues highlight recent advances in understanding immunological vulnerabilities of virally infected cells that persist lifelong and represent the major barrier to a cure.
Review synthesizes research on NK cells' role in cancer immunity and their potential in therapeutics through bioengineering, immune checkpoint inhibitors, and cell engagers, highlighting ongoing preclinical and clinical trials.
Via BigField GEG Tech
|
Scooped by
Gilbert C FAURE
February 23, 11:27 AM
|
Breakthrough sickle cell treatments are available in the U.S., but their high cost is forcing insurers to get creative.
|
Scooped by
Gilbert C FAURE
February 23, 10:36 AM
|
|
Cancer Letters
Volume 360, Issue 2, 1 May 2015, Pages 302–309
Original Articles Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinomaZhenyu Xiaoa, 1, Haniee Chunga, 1, Babak Banana, Pamela T. Manningb, Katherine C. Otta, Shin Linc,Benjamin J. Capocciaa, Vijay Subramaniana, Ronald R. Hiebschb, Gundumi A. Upadhyaa, Thalachallour Mohanakumara, e, William A. Frazierd, Yiing Lina, , , William C. Chapmana, , doi:10.1016/j.canlet.2015.02.036
Volume 360, Issue 2, 1 May 2015, Pages 302–309
Original Articles Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinomaZhenyu Xiaoa, 1, Haniee Chunga, 1, Babak Banana, Pamela T. Manningb, Katherine C. Otta, Shin Linc,Benjamin J. Capocciaa, Vijay Subramaniana, Ronald R. Hiebschb, Gundumi A. Upadhyaa, Thalachallour Mohanakumara, e, William A. Frazierd, Yiing Lina, , , William C. Chapmana, , doi:10.1016/j.canlet.2015.02.036